Francisco Hernandez-Ilizaliturri, MD
As lisocabtagene maraleucel (Breyanzi; liso-cel) lately joined the record of FDA-approved CAR T-cell therapies for the remedy of sufferers with relapsed or refractory follicular lymphoma who acquired at the very least 2 prior strains of systemic remedy, there’s not a standardized reply concerning which agent clinicians ought to choose within the third-line setting, as a number of components affect this resolution, in accordance with Francisco Hernandez-Ilizaliturri, MD.1,2
Findings from the section 2 TRANSCEND-FL trial (NCT04245839), which supported the Might 2024 approval of liso-cel on this affected person inhabitants, confirmed that sufferers who acquired the agent (n = 94) achieved an total response fee of 95.7% (95% CI, 89.5%-98.8%). Moreover, at a median comply with up of 16.8 months (95% CI, 16.3-17.0), the median period of response was not reached (NR; 95% CI, 18.04-NR).2
“Now we have many choices to deal with sufferers with follicular lymphoma and greater than ever we have to individualize remedy choice. We’d like to concentrate on the distinct mechanism of motion of every possibility,” Hernandez-Ilizaliturri mentioned in an interview with OncLive®. “We additionally have to [continue to] be taught concerning the exercise, however it’s additionally crucial to concentrate on the short-term and long-term toxicities of every remedy, and how you can deal with sufferers as a result of on the finish of the day these [factors] are going to be the inspiration that we’re going to make use of to pick out an possibility for a given affected person. It’s vital to have data of all of those areas. Each remedy that you choose goes to be a superb remedy, however the hot button is how do you match the affected person that you simply’re seeing within the clinic with the best choice for that affected person?”
Within the interview, Hernandez-Ilizaliturri, detailed components that affect remedy choice for sufferers with relapsed or refractory follicular lymphoma and in addition highlighted the potential of pirtobrutinib (Jaypirca) on this house. Hernandez-Ilizaliturri is the director of Lymphoma Analysis, head of the Lymphoma Translational Analysis Laboratory, a professor of oncology, and an affiliate professor within the Division of Immunology at Roswell Park Complete Most cancers Middle in Buffalo, New York.
OncLive: How has the FDA approval of liso-cel following 2 prior therapies shifted the remedy panorama for sufferers with follicular lymphoma?
Hernandez-Ilizaliturri: Liso-cel is one other commercially accessible CAR T-cell remedy concentrating on CD19. It was beforehand accredited for sufferers with relapsed/refractory massive B-cell lymphoma and now could be accredited for sufferers with B-cell malignancies, particularly indolent lymphomas and persistent lymphocytic leukemia [CLL]. It’s one other software that we’ve to regulate relapsed/refractory B-cell lymphomas and the exercise is in line with what we’ve [observed] with different CAR T-cell therapies. What’s attention-grabbing about liso-cel is the protection profile, as cytokine launch syndrome and neurotoxicities look like much less extreme and fewer frequent. That may encourage use in sufferers, particularly in these with comorbidities.
How do you choose between the a number of CAR T-cell therapies accessible in follicular lymphoma?
That [decision] goes to fluctuate from establishment to establishment, [and] it relies on what product every group has been working with. We [also] have to have a look at the remedy’s security profile as a result of, relying on the affected person we’ve in entrance of us, we could favor 1 product vs one other.
There are different components that will affect the choice of the CAR T-cell product, [such as] the manufacturing time; some early CAR T-cell merchandise [in development] have a shorter turnaround that’s extra appropriate for sufferers who want a fast remedy. As well as, sufferers who could have much less tumor burden, however have comorbidities, might favor a CAR T-cell product that has an extended manufacturing time [because] they might have a ‘safer profile.’
There may be not a generalized reply to what could be the [best] product to decide on. The age of the affected person, comorbidities, tumor burden, and time through which it’s a must to use remedy are variables that affect [decisions, and another factor is] what’s accessible on the establishment the place the affected person can be handled. The coaching that the well being care employees must endure to manage every of these CAR T-cell merchandise [is a consideration too].
How do these components assist inform remedy selections within the second- or third-line settings of follicular lymphoma?
I are inclined to divide these components into patient-related components which has to do with age, comorbidities, organ perform, [and other] components, [such as] how briskly the follicular lymphoma is rising [and] what the grade [of disease] is—grade 1 or grade 2 could also be barely totally different than grade 3A and definitely a lot totally different than 3B, which is now thought of a high-grade lymphoma. Then, we’ve toxicities from prior remedy, that are treatment-related components. What was the prior remedy and ensuing antagonistic results and the way extreme are [they]? We are able to [consider these factors] collectively to pick out the most effective subsequent line of remedy for a given affected person.
Once I discuss to sufferers with follicular lymphoma, I additionally attempt to, if potential, unfold the intervals through which chemotherapy medicine are being administered as a result of chemotherapy brokers in distinction with focused therapies have extra off-target toxicities that may result in everlasting organ harm, [such as] cardiac toxicity, peripheral neuropathy, or, extra regarding, myelodysplasia or secondary leukemias. On the whole, a super sequence of remedy is a few type of chemoimmunotherapy within the first-line setting after which within the second- and third-line setting [we] attempt to faucet into focused brokers to additional improve that point through which sufferers should not uncovered to chemotherapy medicine.
It’s now extra vital than ever to include a affected person’s pursuits and preferences into resolution making as a result of some remedies have logistics that may have an effect on the [treatment] desire. There are sufferers who’re eager to remain near dwelling to obtain remedy or not spend an excessive amount of time within the hospital seeing docs. There are sufferers, alternatively, who wish to get accomplished with remedy sooner [rather] than keep indefinitely on a remedy or keep for a protracted time frame. It’s crucial to have these discussions with sufferers and caregivers.
What’s the potential for the non-covalent BTK inhibitor pirtobrutinib and what might it probably imply for the follicular lymphoma remedy paradigm?
Pirtobrutinib is rising as one other remedy [option] for sufferers with not solely mantle cell lymphoma and CLL, but additionally for these with marginal [zone] and follicular lymphomas. It’s one other software that we are able to use to deal with sufferers, particularly those that are in illiberal to a previous BTK inhibitor or are growing resistance to a covalent BTK inhibitor.
Now we have knowledge on zanubrutinib [Brukinsa] together with obinutuzumab [Gazyva] which confirmed that the [combination] is energetic and effectively tolerated in sufferers with follicular lymphoma within the third-line setting; having pirtobrutinib accessible is one other good therapeutic technique. These remedies could also be extra fascinating in sufferers who’re 75 years outdated or above, the place having a extra particular agent with much less of an off-target impact could show to be efficient and secure.
It’s vital to focus on that follicular lymphoma continues to be a illness that’s primarily recognized in sufferers above the age of 65 and a big variety of sufferers, fortunately, will solely require 2 strains of remedy throughout the time that they’ve lymphoma. There’s a small group of sufferers who would require a third-line [treatment] and past; these are the sufferers who [have disease that is] a problem for any oncologist [to treat].
References
- Oncology (most cancers) / hematologic malignancies approval notifications. FDA. June 26, 2024. Accessed July 12, 2024. bit.ly/4a9JHIt
- FDA grants accelerated approval to lisocabtagene maraleucel for follicular lymphoma. FDA. Might 15, 2024. Accessed July 12, 2024. bit.ly/462f86E
